Opiates TPP RICO 2 — Settlement Summary

Last Modified on 09/25/2026 5:01 pm EDT

In re: National Prescription Opiate Litigation – Third-Party Payor (TPP) RICO 2 Settlement

Summary

This class action settlement arises from the national opioid crisis and involves claims by Third-Party Payors (TPPs) — such as insurers, health plans, and benefit funds — that pharmaceutical manufacturers, distributors, and pharmacies caused them to incur excessive costs for opioid prescriptions and opioid use disorder treatment. Four new settlements totaling **$180 million** have been reached with Allergan, Teva, Janssen, and major pharmacy chains (CVS, Walgreens, and Walmart). The case is pending in the U.S. District Court for the Northern District of Ohio before Judge Dan A. Polster under MDL No. 1:17-md-2804.

Announcements

- **September 23, 2026:** The Court granted **final approval** to the Allergan, Janssen, Teva, and Pharmacies settlements. Final Orders and Judgments are available on the Court Documents page under "2026 Settlements." As a reminder, the claim form deadline is **December 1, 2026**.
- **June 16, 2026:** The Court granted preliminary approval to the 2026 Settlements and determined at the Fairness Hearing whether to certify the TPP Class for these Settlements.
- A prior 2024 settlement with Settling Distributors has already received Final Approval. Class members who previously submitted a claim in that settlement may choose to rely on their previously submitted claim form for the 2026 Settlements.

Settlement Amount

The four 2026 Settlements collectively provide a cash payment of **$180 million**, contributed by the following Settling Defendants:

- Allergan Finance, LLC and certain affiliates
- Teva Pharmaceuticals USA, Inc. and certain affiliates
- Janssen and certain affiliates
- CVS, Walgreens, Walmart, and certain affiliates (collectively, "Settling Pharmacies")

The allocation of settlement proceeds among class members is addressed in the Expert Report of Professor Meredith Rosenthal, available on the Court Documents page. A per-claimant estimate is not published on the settlement website.

Class Period

January 1, 1996 through June 16, 2026.

Filing Deadline

December 1, 2026. Claim Forms must be postmarked (if mailed) or received (if submitted online) on or before this

date. Class members who previously submitted a claim in the prior TPP class settlement with Settling Distributors (the 2024 Settlement) may choose to rely on their previously submitted claim form.

Who Qualifies

The TPP Class includes all entities that:

- Paid and/or were reimbursed for opioid products manufactured, marketed, sold, distributed, or dispensed by any of the Defendants and/or Alleged Opioid Enterprise Members for purposes other than resale; **and/or**
- Paid or incurred costs for treatment, services, or procedures related to the use of, misuse of, addiction to, and/or overdose from opioid products and other opioid drugs, on behalf of individual beneficiaries, insureds, and/or members,

during the class period of January 1, 1996 to June 16, 2026.

The Class specifically includes but is not limited to:

- Private contractors of Federal Health Employee Benefits plans
- Plans for self-insured local governmental entities that have not settled claims in MDL No. 2804
- Managed Medicaid plans
- Plans operating under Medicare Part C and/or D
- Taft-Hartley plans
- ERISA plans

Who Is Excluded

The following are excluded from the TPP Class:

- All federal governmental entities and all state and local governmental entities whose claims have been released by a prior settlement with the Settling Defendants
- Pharmacy Benefit Managers (PBMs)
- Consumers
- Fully insured plan sponsors
- The Settling Defendants and their subsidiaries, affiliates, and controlled persons
- Officers, directors, agents, servants, or employees of any Settling Defendant and the immediate family members of any such persons
- Persons and entities named as Defendants in any of the Actions coordinated under or parallel to MDL No. 2804, unless such persons or entities are only Defendants due to a counter-claim or cross-claim by other Defendant(s)
- Anyone that excluded themselves from the Class

How to File

- **Step 1:** Confirm eligibility. Verify that your organization qualifies as a TPP Class member based on the criteria above and was not excluded.
- **Step 2:** Obtain a Claim Form. Download the Claim Form from the settlement website's "File a Claim" page or from the Court Documents page under 2026 Settlements.
- **Step 3:** Complete the Claim Form. Provide all required information about your organization's payments or reimbursements for opioid prescriptions and/or opioid-related treatment costs during the class period.
- **Step 4:** Submit the Claim Form. Submit the completed form online (must be*received* by December 1, 2026) or by mail (must be *postmarked* by December 1, 2026).
- **Prior Claimants:** If your organization previously submitted a claim in the prior TPP class settlement with Settling Distributors (2024 Settlement), you may choose to rely on that previously submitted claim form

rather than filing a new one.

For questions, contact the Notice and Claims Administrator at **1-877-411-4860**.

Defendants

The **Settling Defendants** in the 2026 Settlements are:

- **Allergan Finance, LLC** and certain affiliates — alleged opioid manufacturer
- **Teva Pharmaceuticals USA, Inc.** and certain affiliates — alleged opioid manufacturer
- **Janssen** and certain affiliates — alleged opioid manufacturer
- **CVS, Walgreens, and Walmart** and certain affiliates — alleged Settling Pharmacies

The **Settling Defendants** in the prior 2024 Settlement were the Settling Distributors (specific entities listed in the 2024 Settlement Agreement available on the Court Documents page).

Alleged conduct: Plaintiffs claim that manufacturers misrepresented the risks and safety of long-term prescription opioid use, distributors failed to properly monitor or report suspicious orders, and pharmacies filled opioid prescriptions that were not written for legitimate medical purposes — all in an effort to sell as many prescription opioids as possible. All Settling Defendants deny these claims and deny any wrongdoing.

Case History

- **2017:** Multi-District Litigation (MDL) No. 1:17-md-2804 consolidated in the U.S. District Court for the Northern District of Ohio before Judge Dan A. Polster.
- **2024:** Settlement reached with Settling Distributors. Preliminary Approval Order entered. Notice disseminated. Final Approval Order entered. (Specific dates listed in 2024 Settlement documents on the Court Documents page.)
- **June 16, 2026:** Court granted preliminary approval to the four 2026 Settlements (Allergan, Janssen, Teva, and Pharmacies). Amended Preliminary Approval Orders issued for each settlement.
- **August 13, 2026:** Deadline for class members to opt out (exclude themselves) from the TPP Class or to file objections and/or notices of intention to speak at the Fairness Hearing.
- **September 23, 2026:** Court granted final approval to the Allergan, Janssen, Teva, and Pharmacies settlements. Final Orders and Judgments entered for each settling defendant group.
- **December 1, 2026:** Claim filing deadline.

Source

Settlement website homepage and Court Documents page for *In re: National Prescription Opiate Litigation*, No. 1:17-md-2804 (N.D. Ohio).
Phone: 1-877-411-4860

Last Updated

2026-09-25

Reviewer Flags

- **Changes from previous version:**
  - **Announcements section updated (Homepage):** Added new September 23, 2026 announcement that the Court granted final approval to all four 2026 Settlements (Allergan, Janssen, Teva, and Pharmacies). Removed the announcement about Motions for Final Approval being filed, as those are

now superseded by the final approval grants. Removed the June 17, 2026 announcement about the public announcement of settlements, as this is no longer time-sensitive news relative to the final approval.
    - **Case History section updated (Court Documents page and Homepage):** Added September 23, 2026 entry for the Court granting final approval and entry of Final Orders and Judgments for all four settling defendant groups. Removed the "Pending: Fairness Hearing" entry, as the hearing has now concluded and final approval has been granted.
    - **Last Updated date changed** from 2026-09-22 to 2026-09-25.
- **Homepage:** Provided the September 23, 2026 final approval announcement, reminder of the December 1, 2026 claim deadline, and all other existing settlement details (class definition, exclusions, settlement amount, class period, filing deadline, opt-out/objection deadline, Settling Defendants, alleged conduct, administrator phone number).
- **Court Documents page:** Confirmed final approval by listing the Final Orders and Judgments for Allergan, Janssen, Teva, and Pharmacies as filed documents under "2026 Settlements." Also confirmed the continued availability of 2024 Settlement documents including the Final Approval Order.
- **Potential flag — Per-claimant estimate:** No individual payment estimate is available on either source page. The allocation methodology is addressed in Professor Rosenthal's expert report (available on the Court Documents page) but no summary figures are stated.
- **Potential flag — 2024 Settlement distributor defendants:** The specific names of the Settling Distributors from the 2024 Settlement are not listed on either monitored page. FRS may wish to consult the 2024 Settlement Agreement document directly.
- **Potential flag — Distribution timeline:** Now that final approval has been granted, FRS staff should monitor the settlement website for announcements regarding the distribution schedule and any claims processing updates.
- **No internal contradictions identified.**